Bausch & Lomb sale

Bausch & Lomb, the eye care company, has agreed to be sold to the Canadian healthcare company Valeant Pharmaceuticals for about $US8.7 billion ($9 billion). Valeant will pay $US4.5 billion to the investor group that owns B&L, led by private equity firm Warburg Pincus. It will also spend about $US4.2 billion to repay B&L's debt.

By InvestSMART · 29 May 2013

By InvestSMART ·
29 May 2013

Share

Comments

Print

Bausch & Lomb, the eye care company, has agreed to be sold to the Canadian healthcare company Valeant Pharmaceuticals for about $US8.7 billion ($9 billion). Valeant will pay $US4.5 billion to the investor group that owns B&L, led by private equity firm Warburg Pincus. It will also spend about $US4.2 billion to repay B&L's debt.

Share this article and show your support

Proudly

Bausch & Lomb sale

{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}

{{ completedStep1 ? 'Authentication & Security' : content.trialHeading.replace('{0}', user.FirstName) }}

{{ content.upgradeHeading.replace('{0}', user.FirstName) }}

Updating information

Please wait ...

Your membership to InvestSMART Group recently failed to renew.

You've recently updated your payment details.

Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial

Please click on the ACTIVATE button to finalise your membership

Unsuccessful registration

Forgotten password